Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin

[1]  Victor Minor.  Ein neues Verfahren zu der klinischen Untersuchung der Schweißabsonderung , 2005, Deutsche Zeitschrift für Nervenheilkunde.

[2]  H. E. Torebjörk,et al.  Limitation of sensitization to injured parts of receptive fields in human skin C-nociceptors , 1996, Experimental Brain Research.

[3]  H. Krämer,et al.  Assessment of the neurogenic flare reaction in small-fiber neuropathies , 2002, Neurology.

[4]  D. Walther,et al.  Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies , 2002, Annals of neurology.

[5]  Jürgen Schüttler,et al.  A New Model of Electrically Evoked Pain and Hyperalgesia in Human Skin: The Effects of Intravenous Alfentanil, S (+)-ketamine, and Lidocaine , 2001, Anesthesiology.

[6]  H. Göbel,et al.  Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes , 2001, Pain.

[7]  F. Erbguth,et al.  Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometry , 2001, The British journal of dermatology.

[8]  K. Shimizu,et al.  [Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles]. , 2000, Nippon Ganka Gakkai zasshi.

[9]  M. Brin,et al.  Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study , 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[10]  M. Schmelz,et al.  Electrically evoked neuropeptide release and neurogenic inflammation differ between rat and human skin , 2000, The Journal of physiology.

[11]  C. Weidner,et al.  Acute effects of substance P and calcitonin gene-related peptide in human skin--a microdialysis study. , 2000, The Journal of investigative dermatology.

[12]  S. Silberstein,et al.  Botulinum Toxin Type A as a Migraine Preventive Treatment , 2000 .

[13]  K. Foster,et al.  Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. , 2000, Biochemical pharmacology.

[14]  R. Dengler,et al.  Treatment of Tension‐type Headache With Botulinum Toxin Type A: A Double‐Blind, Placebo‐Controlled Study , 2000, Headache.

[15]  M. Porta.  A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm , 2000, Pain.

[16]  H. E. Torebjörk,et al.  Which nerve fibers mediate the axon reflex flare in human skin? , 2000, Neuroreport.

[17]  M. Porta.  Comparative trial of botulinum toxin type A and methylprednisolone for the treatment of tension-type headache , 2000, Current review of pain.

[18]  K. Foster,et al.  Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. , 2000, Toxicon : official journal of the International Society on Toxinology.

[19]  F. Erbguth,et al.  Sudomotor testing discriminates between subjects with and without antibodies against botulinum toxin A—A preliminary observation , 2000, Movement disorders : official journal of the Movement Disorder Society.

[20]  S. Silberstein,et al.  Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. , 2000, Headache.

[21]  P. Mantyh,et al.  Transmission of chronic nociception by spinal neurons expressing the substance P receptor. , 1999, Science.

[22]  H. E. Torebjörk,et al.  Functional Attributes Discriminating Mechano-Insensitive and Mechano-Responsive C Nociceptors in Human Skin , 1999, The Journal of Neuroscience.

[23]  M. Tsuda,et al.  In vivo pathway of thermal hyperalgesia by intrathecal administration of α,β‐methylene ATP in mouse spinal cord: Involvement of the glutamate‐NMDA receptor system , 1999 .

[24]  X. Hua,et al.  Intrathecal substance P-induced thermal hyperalgesia and spinal release of prostaglandin E2 and amino acids , 1999, Neuroscience.

[25]  M. Tsuda,et al.  In vivo pathway of thermal hyperalgesia by intrathecal administration of alpha,beta-methylene ATP in mouse spinal cord: involvement of the glutamate-NMDA receptor system. , 1999, British journal of pharmacology.

[26]  SNAP‐25 and syntaxin, but not synaptobrevin 2, cooperate in the regulated release of nerve growth factor , 1998, Neuroreport.

[27]  B. Neundörfer,et al.  Spatial extension of sudomotor axon reflex sweating in human skin. , 1998, Journal of the autonomic nervous system.

[28]  P. Holzer,et al.  Neurogenic vasodilatation and plasma leakage in the skin. , 1998, General pharmacology.

[29]  K. Foster,et al.  Capsaicin stimulates release of substance P from dorsal root ganglion neurons via two distinct mechanisms. , 1997, Biochemical Society transactions.

[30]  M. Schmelz,et al.  Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis , 1997, Neuroscience Letters.

[31]  D. F. Gladish,et al.  Botulinum Toxin Injection for Cervicogenic Headache , 1997, Headache.

[32]  S. Jeftinija,et al.  Cultured astrocytes express proteins involved in vesicular glutamate release , 1997, Brain Research.

[33]  M. Brin.  Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology , 1997, Muscle & nerve. Supplement.

[34]  H. Schutta,et al.  Botulinum toxin–a possible new treatment for axillary hyperhidrosis , 1996, Clinical and experimental dermatology.

[35]  K. Arimura,et al.  Extrafusal and intrafusal muscle effects in experimental botulinum toxin‐A injection , 1996, Muscle & nerve.

[36]  R. Laskawi,et al.  Frey's syndrome: treatment with botulinum toxin. , 1995, Acta oto-laryngologica.

[37]  B. Jabbari,et al.  Botulinum toxin A for spasticity, muscle spasms, and rigidity , 1995, Neurology.

[38]  E. Neale,et al.  Neurospecific binding, internalization, and retrograde axonal transport. , 1995, Current topics in microbiology and immunology.

[39]  W. P. Cheshire,et al.  Botulinum toxin in the treatment of myofascial pain syndrome , 1994, Pain.

[40]  T. Sand,et al.  Tension Headache: Botulinum Toxin Paralysis of Temporal Muscles , 1994, Headache.

[41]  M. Koltzenburg,et al.  Nociceptor modulated central sensitization causes mechanical hyperalgesia in acute chemogenic and chronic neuropathic pain. , 1994, Brain : a journal of neurology.

[42]  H. Yokosawa,et al.  Exogenous zinc ion is required for inhibitory activity of botulinum neurotoxin C1 against norepinephrine release and its endopeptidase activity toward substance P. , 1994, Biochemistry and molecular biology international.

[43]  K. Schwartz,et al.  Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia , 1993, Neurology.

[44]  M. Verhage,et al.  Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. , 1992, The Journal of biological chemistry.

[45]  R. LaMotte,et al.  Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. , 1991, Journal of neurophysiology.

[46]  R. Pamphlett.  Early terminal and nodal sprouting of motor axons after botulinum toxin , 1989, Journal of the Neurological Sciences.

[47]  R. Meyer,et al.  Antidromic nerve stimulation in monkey does not sensitize unmyelinated nociceptors to heat , 1988, Brain Research.

[48]  R. Wilkins,et al.  THE LOCAL SWEAT RESPONSE TO FARADIC STIMULATION , 1938 .